# Journal of Cardiovascular Magnetic Resonance



Poster presentation

**Open Access** 

# Gender related differences in left ventricular remodelling in non-ischemic dilated cardiomyopathy- a structural and functional analysis by cardiovascular magnetic resonance

Stephanie Lehrke\*, Michael Schöb, Henning Steen, Philipp Ehlermann, Helmut Kemmling, Dirk Lossnitzer, Constanze Merten, Grigorius Korosoglou, Evangelos Giannitsis and Hugo A Katus

Address: Medizinische Universitätsklinik Heidelberg, Heidelberg, Germany

from 13th Annual SCMR Scientific Sessions Phoenix, AZ, USA. 21-24 January 2010

Published: 21 January 2010

Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):P183 doi:10.1186/1532-429X-12-S1-P183

This abstract is available from: http://jcmr-online.com/content/12/S1/P183

© 2010 Lehrke et al; licensee BioMed Central Ltd.

## Introduction

The impact of gender on morbidity, mortality and the response to medical therapy in cardiovascular disorders, including cardiomyopathies, has long been recognized. Recently, gender- related differences in the cardiac phenotype of patients with hypertrophic cardiomyopathy were identified using contrast-enhanced cardiovascular magnetic resonance (CE-CMR). However, no data exists in patients with non- ischemic dilated cardiomyopathy (DCM).

#### **Objective**

Goal of this study was to use CE-CMR to determine gender-associated differences in left ventricular (LV) remodelling and the occurrence of myocardial fibrosis in patients with DCM. As gender impacts cardiac structure and function even in normal hearts, results were interpreted in relation to those obtained from a healthy reference population.

#### **Methods**

CE-CMR was performed in 192 consecutive patients with DCM (age  $51.9 \pm 2.1$  yrs.; 47 females) and in 80 controls free from cardiovascular disease (age  $50.2 \pm 1.4$  yrs.; 41 females) on a 1.5 T clinical scanner. LV volumes, systolic function and mass were derived from SSFP cine images.

The LV- remodelling index (LVRI) was calculated as mass/end-diastolic volume.

# **Results**

Males and females with DCM were comparable with regard to baseline characteristics, including heart failure




Figure I
Left-ventricular remodelling index (LVRI) according to gender and presence of DCM.

<sup>\*</sup> Corresponding author

Table I: CMR results of LV volumetry according to gender and disease

	Females		Males	
	controls (n = 41)	DCM (n = 47)	controls (n = 39)	DCM (n = 147)
LV-EF (%)	68.8 ± 1	38 ± 2.1*	65.4 ± 1.4	36.4 ± 1.2*
LV- EDV (ml)	125.3 ± 3.2	216.4 ± 12.8*	161.9 ± 5.1#	267.5 ± 7.8*#
LV-EDV/BSA (ml/m²)	71.6 ± 1.6	123 ± 7.1*	81.3 ± 1.9#	131.7 ± 3.9*
LV-ESV (ml)	39.6 ± 1.8	140.7 ± 14.3*	56.6 ± 3.1#	179.4 ± 8.4*#
LV- mass (g)	59.6 ± 1.7	116.1 ± 6*	92.4 ± 3.3#	168.7 ± 10.9*#
LV-mass/BSA (g/m²)	$33.9 \pm 0.7$	64.5 ± 3.8*	44.4 ± 1.5#	82.3 ± 5.1*#
LVRI (g/ml)	0.46 (0.43- 0.51)	0.55 (0.47-0.63)*	0.57 (0.49-0.63)#	0.6 (0.51-0.69)#

<sup>\*</sup>p < 0.01 vs. respective controls; \*p < 0.01 vs. respective female group

medication and NYHA classification. Table 1 depicts the results of LV volumetry:

Gender- associated differences found in controls were mainly sustained among DCM patients. Regardless of gender, DCM patients exhibited a decline of systolic function and an increase of volumes and myocardial mass compared to controls. Interestingly, the LVRI showed a significant increase only in females, reflecting a higher increase in LV mass relative to the increase in EDV compared to males (Figure 1). Gender was not associated with the presence of LGE (58/138<sub>DCMmales</sub> vs. 14/46<sub>DCMfemales</sub>, p = ns).

## Conclusion

This study provides first evidence for the influence of gender on the remodelling process in patients with DCM, as women seem to experience a more pronounced hypertrophy relative to dilatation. If confirmed in future research, this finding may have important implications on the therapeutic approach in women with DCM.

Publish with **Bio Med Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- $\bullet$  peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- $\bullet$  yours you keep the copyright

Submit your manuscript here: http://www.biomedcentral.com/info/publishing\_adv.asp

